<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298415</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-0501</org_study_id>
    <nct_id>NCT00298415</nct_id>
  </id_info>
  <brief_title>Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase III Study of Monotherapy by Gemcitabine or Vinorelbine Comparing to Doublet by Carboplatin and Paclitaxel Among Elderly Patients With Stage IIIB/IV NSCLC (Obligatory Second-line by Erlotinib)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The last ASCO recommendations in 2003 for the treatment of a CBNPC of stage IIIB/IV of
      elderly people, are to manage a monochemotherapy. Paclitaxel in association with carboplatin
      is feasible in elderly patients and the retrospective analysis of two studies of the
      comparing SWOG, one this association with that of cisplatine and vinorelbine and the other
      cisplatine only with cisplatine and vinorelbine, showed among 117 the 70 years old patients
      and more, the absence of significant difference of survival and toxicity compared to the
      younger patients. The study recently published of Lilenbaum and Al shows that among patients
      with bad PS, association carboplatine and paclitaxel do better than the paclitaxel only. The
      paclitaxel managed in weekly form is likely of a better activity by exposing the cancerous
      cells in a repeated way with shorter intervals without allowing the emergence of resistant
      clones and by allowing an increase in the intensity of amount. This mode of administration
      appeared at the same time effective and tolerated very well among patients of more than 70
      years. The weekly association of carboplatin and paclitaxel was tested in phase II and showed
      a rate of response of 14% and one survival 1 year from 31% a randomized test (not dedicated
      to the old person) of phase II to 3 arms was led by Belani et al.. The best combination of
      carboplatine + paclitaxel weekly proved to be that associating paclitaxel 100mg/m² 3 weeks
      out of 4 and carboplatine AUC 6 in J1 with J1 = J29. A test of phase II dedicated the 70
      years old to patients and more was carried out in France taking again this association
      carboplatine (AUC 6) every 4 weeks and paclitaxel weekly (90 mg/m² J1, J8 and J15). This test
      having included 51 patients highlighted a median of 10,42 months survival (IC 95%:
      7,29-17,05)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It thus seemed to us justified to compare a standard arm, the vinorelbine or the gemcitabine
      (with the choice of the center) in monotherapy with an experimental arm, association
      carboplatine + paclitaxel. To avoid skewing the results by the introduction of a second line
      to the choice of the investigator, we chose to force it. It is thus the erlotinib which in a
      recent test presented by the NCIC at the ASCO 2004 proved its effectiveness in second or
      third line at the same time in term of response but more especially survival compared to the
      purely palliative care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy (mono)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy (doublet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Carboplatin</intervention_name>
    <description>Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Treatment after progression : Erlotinib 150 mg/day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monotherapy (gemcitabine or vinorelbine)</intervention_name>
    <description>Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Treatment after progression : Erlotinib 150mg/day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically / cytologically proven NSCLC stage IIIB or IV

          -  age &gt;= 70 years old and &lt; 90 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth QUOIX, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH - Pneumologie</name>
      <address>
        <city>Belfort</city>
        <zip>90000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besancon - Pneumologie</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Pneumologie</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr</url>
    <description>IFCT website</description>
  </link>
  <reference>
    <citation>Pujol JL, Milleron B, Molinier O, Quoix E, Depierre A, Breton JL, Gervais R, Debieuvre D, Hominal S, Namouni F, Tonelli D. Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. J Thorac Oncol. 2006 May;1(4):328-34.</citation>
    <PMID>17409879</PMID>
  </reference>
  <results_reference>
    <citation>Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011 Sep 17;378(9796):1079-88. doi: 10.1016/S0140-6736(11)60780-0. Epub 2011 Aug 8.</citation>
    <PMID>21831418</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2006</study_first_submitted>
  <study_first_submitted_qc>March 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2006</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>2-years survival</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

